today. you, our during good beyond. and afternoon, accomplished Thank provide Thank and recap Bob, comments everyone. brief for In and turn then this call the strategic you XXXX and for joining a my what afternoon to of expectations plans I’ll was XXXX
year takeaways. there look completed, we back three think the just are I key at As
First, in. in we effectively executed on our markets positions strengthening our and we health public compete strategy of building the leadership
in continue Secondly, which revenue we longer-term core functions scale leverage progress prudent to our we investments And may key R&D to to expect build we better competitive to third, to for competencies growth. sustainable investments, will strategic contribute advantage.
stone Let deliveries transition few me each Anthrax the execution. preparedness the against the to AVXXXX of efforts as threat AVXXXX these In our minutes we of candidate corner expand Vaccine U.S. strategy Anthrax. and beginning BioThrax next of generation starting points, initiated from XXXX, take the with on a of three government’s
$XXX Related of doses delivered period first million be for over to BARDA to at XX valid option this, its contract AVXXXX XX approximately month exercised million.
supply Next, smallpox procurement of FDA XX-year franchise. against and response we for the the threat the strides principle government’s $X made contract great dose billion smallpox. single smallpox a our tool approved of secured vaccine only We with U.S. ACAMXXXX continued the
for million complications. the $XXX tenure of our approved contract a also continued FDA supply VIGIV, vaccine therapeutic for We secured smallpox
U.S. XX-year approved government, of our supply from Botulism anticipated the an million commitment million Next, a FDA Antitoxin. of $XX we part secured continued commitment the as XXX BAT,
in invest and we Adapt of NARCAN continued integration and further health Nasal the Spray travel completed facts tax the franchises. acquisitions, the finally, scale And to Pharma and and
securing successfully billion So portfolio we during positions strengthened contracts across by products of summarize, our U.S. XXXX, worth leadership $X with of the over our government. to long-term procurement
have Anthrax, each key of profitably result, smallpox, our diversifying in revenue. product revenue medical franchises mix. three overdose we through customer to in and to those follow reversal, excess $XXX our opioid being million countermeasure and As which position clear a now A in commitment of annual grow a generate while are on
away second R&D. to relates take key The
FLU-IGIV analysis number completing During our furthering XXXX, X stages A cholera X and we Phase R&D initiating various addressing vaccine, Phase progress auto development. of programs combination This completing for various of pediatric product made approved through a our injector the advancing portfolio a study candidates device various a study significant in Vaxchora seasonal advancing included Phase of study programs AVXXXX X a threats drug chemical influenza addressing the interim crisis. opioid therapeutics for our based for
results both We EMA updated from recently program initiating candidate, our a efficacy. development Phase X to presented Phase of our anticipate alignment Phase of endpoint study our received of X also later for FDA and study involving We of use year. and this more a chikungunya surrogate X the pursue study vaccine this
The to relates last takeaway scale.
bottom execution made results. progress business long term, further the goals infrastructure line at growth same operating our expense in our we scaling and significant into against translated capabilities managing through to continue strong drive our The people, strong to in top while equally over base. XXXX, targeted During investments time and the financial
what as which the one-year drove we the as I line, growth, numerous compared top executed a contracts the over goal of integrated and goal organic established billion Adapt just to in revenue, first XXXX. outlined. over as acquisitions, Notably, corporate revenue marks fully and PaxVax we of the do XXXX advance when grew achievement On we set XX%, recorded out to in in we $X
income in EBITDA profitability XX%, of We also strong net generated XX% with year-over-year and increases respectively. and adjusted adjusted
progress over of for year. achieved chapter the like thank course at XXXX, extraordinary we and closed a take colleagues to opportunity the to company team the we I'd X,XXX the the As on leadership as my Emergent the
hard momentum efforts, XXXX with and of entering we're a with their work As confidence. and result
So, bit talk and forward let's look XXXX. a about
again to between remaining once growth. our this XXXX manage as As Analyst Day, the our at disciplined we while intend years over double we Investor discussed XXXX, and five we revenues November next and
Our and expanding investments our five on in principles. continue to and leadership strategy threat excellence. current positions health is capabilities, innovation, public make strategy centered new markets in includes operational This and core
our for continued growth of also variety will will touch second, company. which the the capabilities; the like a that prepared executing core growth his scalable in established a prepared M&A; This R&D backdrop, my established With to our spend drive as year, remarks. Rich goals, of portfolio; for on culture. We've building ambitious XXXX, time business; First, further coming fifth, our third, strengthening through comments. and evolve which continuing we've fourth, where the balance in I operational is of goals to financial
ship are from AVXXXX ongoing our the plan course of in with broader the continuing Anthrax, U.S. to against threat to year, the BioThrax Anthrax of and which to in BioThrax Beginning our of over preparedness the government's transition support the stockpile ongoing elements franchise we supporting doses both Vaccines, AVXXXX. Anthrax, of the thereby while
vaccines a the revenue to return of number levels. of guidance the mix two annual a both in and of timing That XXXX historic $XXX dependent range $XXX contribution upon for The our between factors. contemplates said, and of exact a revenue, million combined is products the million
which and smallpox VIGIV both XXXX. ACAMXXXX franchise, our Turning strong contributions we therapeutic, the both anticipate in consist of vaccine the from to
and Our government. revenue between revenue consisting shipments million of to ACAMXXXX XXXX U.S. primarily contemplates guidance $XXX $XXX of million, the
year doses XX government XXXX, the doses XXXX to U.S. that as million similar award. contract delivery million $XXX in approximately approximately the completed a committed Recall base of with and of buy XXXX. expect We in value of in a award all part
their anticipated to last for countermeasure international year, multi-year nature medical customers. This example $XXX threat the $XXX latest contract also a business. health continued procurement ACAMXXXX. win signed a of U.S.-allied procurement public ACAMXXXX nation million of contract The we the On note, sales million support preparedness is includes in with global of good a to range that of
similarly the and for and threats. goals that consider outside them of U.S., response, with aligned chemical partnerships we against threat their assist order preparedness biologic look around in organizations capabilities When we entities have to with international various readiness a the
in includes with branded along NARCAN rising $XXX million Spray Next, and This the Nasal to $XXX co-prescription business growth entering an the the assumption range of during we sometime legislation, sales adopting of continued competition two million. between expect market states additional XXXX.
areas. We will on focus continue to three
awareness U.S. NARCAN. Surgeon of of the highlighted ready naloxone statement; of First, affordability second, advisory through of and third, maintaining increasing General's expanding variety distribution and accessibility access the importance programs; availability naloxone the to and of having a by risks as opioids
meaningful a focus, we continue addressing feel the opioid that will have this Spray NARCAN crisis. With Nasal impact on confident to
the related address their a filed me our week. that Nasal reached February agreement Spray. settlement we XX, on While generic this to topic, seeking let we're a the announced litigation ongoing we earlier NARCAN in Perrigo version market of with to X-K we've ANDA, On
license Per ANDA they the future earlier agreement, about. also been scheduled that February settlement remains XX, subject arguments we In a Wednesday, on XX. has regarding including litigation filers of XXXX come January final or for certain Teva outcome of as February litigation by court the for Teva the effective approvals. current announced matter, be This to the under date customary will or closing circumstances, next against Perrigo's litigation should the
our about business. say me a let CDMO Next, words services few
of approaches, viral, molecule-to-market Emergent's and reoriented mammalian, customers. technology to microbial, of contract pharma pillars. three continue both on out advanced support biotech as we platform the of and We have our in portfolio focus manufacturing external business development as centering growth, therapy our growing to well our CDMO the broad growth and build supporting plasma, services strategic Factoring
management. marketing pipeline First, commercial, include sales and portfolio which international expansion and domestic and penetration, and
our where as operational, extend expertise as multiple technological Second, modalities, our well to capacity striving and we're capabilities. and our biologic harmonize across systems, expand processes
offering. with management, a on our project And and in development focus centricity, customers the finally, a of relationships molecule-to-market of customer governance with focused comprehensive consistent
and and remember, in Baltimore. you and to million are As project may product site's year state-of-the-art completing capacity to in expanded in our services. approximately drug announced facility XXXX access actively invest engaging this with at this this anticipate customers discussions capabilities $XX our already we for We decision
generating We beginning investment XXXX. expect to in on begin positive return this a
and operations CDMO be growing performance integral to of our the we consistent continue contributor broad to broadly, company, for looked more offering. the business an product of overall financial a Speaking to solutions and component the and and
a comments the on we advance to auto let related approval one business, goals over invest pipeline in various me brief the Before of turning we will opioid our devices constructs components In R&D. XXXX. development of injectors [now crisis. and in XXXX spray to within] to key our one finish Rich, chemical addressing call in with our regulatory our filing couple programs for anticipate market, addressing and syringe development naloxone additional and and Of medical in programs, specifically countermeasures threats, the devices-based and continue
In our platforms. the continue public therapeutics with in to business, threats invest pipeline antibody to we will health our address
Regarding our readout of then leading therapeutic which QX hospitalized capitalize year patients development and occurred therapeutic in the potential database A data with program, a Phase influenza completion X we and Phase year. this last X the for initiation plan in lock, FLU-IGIV, and to in later
cholera in health our business, Area positive Vaxchora, EU, single-dose for valid of the the product anticipate authorization market will the a recently received from travel If opinion FDA-approved well Economic received, be couple a as as European XX In states our within which countries. in of leading the we months. member to oral EMA, for all it vaccine
chikungunya program, to with data by the trial to VLP X X toward late Phase as last And supported we year. compelling our CHIKV continue and on Phase reported the launching we of work respect presented
infectious – speak topic and moment the take global related of emerging on the ongoing a we're crisis to it diseases, to to I make While coronavirus. the want
and to wheelhouse. As of our solution The the pandemic is where this being absence rise Emergent options. there especially to an squarely push of to of capabilities preventative is is organization, response treatment emerging in committed responses, develop part an COVID-XX against support and the disease approved infectious
public challenging infrastructure We bear respond experience, to in threat. bring have and solve helping and for this to to health the increasingly expertise considerable
several to and to marshal events our capability. how on including for it's commercial government, the we're and resources apprised or as development a as our utilizing progress organizations, and whether contract vaccine, keep parties extensive Currently you manufacturing the therapeutic, with We'll posted unfold. working NGOs U.S. and best diagnostic capabilities,
equally in growth while goals continually another year and So, was in The the well XXXX on our to our great accelerate long-term. to operationally, remain to the candidates M&A, to opportunities it and drive units. organic solid as innovation value over to focus be lining in summarize, financially. ability shareholder grow all advancement towards I for of management of as XXXX, confident team is through are across pipeline our and organically, strategic leveraging Emergent committed business our up successful achieving
over more With Rich? about provide that, Rich XXXX call thoughts to our the to I'll turn and now the detail results XXXX. on
